Company news from the 05/15/07 news brief

Share this article:
Bristol-Myers Squibb announced it would pay up to $192 million in a deal with Isis Pharmaceuticals to develop and market a new line of drugs for the prevention and treatment of cardiovascular disease. The drugs will target PCSK9, which helps regulate the amount of cholesterol in the bloodstream. Under the terms of the deal, Bristol-Myers Squibb will pay Isis a $15 million licensing fee for access to Isis’ PCSK9 research program, contribute at least $9 million to research funding over three years, and pay up to $168 million in fees for the initial drug development. Bristol-Myers Squibb will also pay Isis royalties on drug sales. While Bristol-Myers Squibb will fund the collaboration, both companies will be responsible for preclinical development.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.